| Gene name: | PTTG1 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | HCT116 |
| Experiment: | Knockdown//BrdU assay//SA-β-gal activity assay |
| Description: | With similar cell numbers plated, HCT116 WT and PTTG1-/- cells exhibited similar absorbance (OD 0.4) at 0 hour. After 48 hours, HCT116 WT cells showed an absorbance of 1.8 and PTTG1/- cells 1.3, suggesting that HCT116 PTTG1-/- cell number were less than WT. Reintroduction of PTTG1 into HCT116 PTTG1/- cells (PTTG1-/- +PTTG1) increased cell number after 48 hours , and these cells exhibited an OD value of 2.1 (1.6 fold increase compared to PTTG1-/- expressing an empty vector).After doxorubicin (0.005 uM) treatment, 56% of HCT116 PTTG1-/- cells exhibited enhanced β–Gal staining, compared to 5% of WT cells，we reintroduced PTTG1 into HCT116 PTTG1-/- cells，β–Gal staining indicated fewer senescent cells when PTTG1 was re-introduced (6%) than in control HCT116 PTTG1-/- cells . |
| Target gene: | P21 |
| Official symbol(s): | P21 |
| R-AG-Target gene: | -- |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot |
| Target gene description: | To test the requirement of p21 for enhanced senescence observed in PTTG1-/- cells, we knocked down p21 and then assessed effects of cell treatments. PTTG1-/- HCT116 cells exhibited 21% senescent cells when p21 was suppressed, compared to 58% in control siRNA treated cells, indicating the requirement for p21 in PTTG1 mediated senescence. Moreover, HCT116 PTTG1-/- cells possess higher p21 levels. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...